(Date:5/16/2008)...asize the Importance of Oral and Overall Health, ...ental insurer United,Concordia Dental is celebrati...ral Health America and the British Dental Health F... to overall health. Beginning May 18,this year,s ...rst time,making it the largest independent intern...
(Date:5/16/2008)...d at the American Society of Clinical Oncology mee...ment practice in about 25 percent of patients with...s to the way colorectal cancers will be staged. ,...e (NCI) SEER population-based statistic registries...ata, shows that outcomes of patients with positive...
(Date:5/16/2008)...sufferers gain benefit from calcitriol, an oral fo...- Taking activated vitamin D may cut the risk of d...dney disease by about one quarter, a new study sug...1,400 patients, those being treated with calcitrio...overall risk of death lowered by 26 percent when c...
(Date:5/16/2008)...t beneath the lining of the uterus (submucosal) ar...ter uterine artery embolization (UAE) but usually ... study. , The study included 49 patients with 1...e and after UAE. The study found that 39 of these ...ometrial cavity after UAE, said Sachit Verma, MD, ...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2(Date:5/16/2008)...ting that TYKERB and trastuzumab together resulted...on-free survival (PFS), -- Combining TYKERB and t...f the HER2 receptor may create a more complete HER...ERB alone despite patients,previous treatment wit... LONDON and PHILADELPHIA, May 16 /PRNewswire-USNew...
(Date:5/16/2008)...er Novel Approach to Blood ...swire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), a...vel small,molecule therapeutics, announced today t...tor Antagonist (DARA), showed statistically signif...y in patients with mild to,moderate hypertension. ...
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...table Tolerability Profile, with Low I...AKE, N.J., May 15 /- The investigatio...9) demonstrated activity in a,heavily pretreated p...atic,breast cancer, according to results of a mult...uggests that eribulin mesylate has a manageable,to...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 1ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 2ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 3ACRIN Study Endorses Virtual Colonoscopy Validation for Colon CAD Software Maker Medicsight plc 440 4Naturally occurring apple compounds reduce risk of pancreatic cancer 668 1Naturally occurring apple compounds reduce risk of pancreatic cancer 668 2Type of ICU Influences Lung Injury Survival 2811 1Type of ICU Influences Lung Injury Survival 2811 2Study Finds Benefits With Drug Coated Stents 2808 1Study Finds Benefits With Drug Coated Stents 2808 2Study Finds Benefits With Drug Coated Stents 2808 3...BUSINESS WIRE)--Jun 20, 2007 - Array BioPharma,Inc...ta on its MEK,inhibitor, ARRY-162, and its p38 inh...the Annual European Congress of Rheumatology,(EULA...ssociation,of Inflammation Societies, (IAIS) 8th W...rk., ARRY-162 / MEK Inhibitor Phase 1 Results , Ar...
...chusetts --- June,20, 2007 --- Millipore Corporati...ing its ReNcell neural stem cell lines. The,resea...at,University College London and ReNeuron Group pl...pore was announced in 2006. ,The data will be pres...ientist for Millipore’s Bioprocess Division,...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: